BioSpace News Archive

Deals

Medpace Holdings, Inc. Announces Pricing of Secondary Offering of Common Stock by Selling Shareholder at $55.50 Per Share

Medpace Holdings, Inc. today announced the pricing of the previously announced secondary offering of 5,224,997 shares of its common stock by investment funds affiliated with Cinven Capital Management

August 22, 2018
·
4 min read
FDA

Dompé receives FDA approval of Oxervate™ eye drops (cenegermin-bkbj ophthalmic solution), first-in-class recombinant human nerve growth factor with potential to completely heal rare neurotrophic keratitis

Oxervate is the first-ever application of a human nerve growth factor as drug or treatment, and is the first-ever topical biologic medication approved in ophthalmology.

August 22, 2018
·
9 min read
Biotech Beach

AVITA Medical Announces Commencement of Manufacturing of RECELL® Device in Newly Acquired Facility in Preparation for Planned U.S. Launch

AVITA Medical today announced the successful completion of multiple production runs for the RECELL Device® within its newly acquired manufacturing facility in Ventura, California.

August 22, 2018
·
5 min read
BioCapital

FDA Rejects Allergan’s Uterine Fibroid Treatment Following EMA Concerns Over Liver Damage

The U.S. Food and Drug Administration rejected Allergan’s New Drug Application for (ulipristal acetate).

August 22, 2018
·
3 min read
·
Alex Keown
Business

AbbVie Exercises Option to Develop Argenx Immuno-Oncology Compound

Chicago-based AbbVie has exercised its exclusive license option to develop and commercialize Belgium-based Argenx’s ARGX-115. The compound is an antibody that targets novel immuno-oncology target glycoprotein A repetitions predominant (GARP).

August 22, 2018
·
2 min read
·
Mark Terry
Business

Sierra Oncology Acquires Gilead’s Momelotinib in $198 Million Deal

Vancouver, British Columbia-based Sierra Oncology acquired momelotinib from Gilead Sciences in a deal that could hit $198 million.

August 22, 2018
·
3 min read
·
Mark Terry
Business

Evotec and Novo Nordisk Ink Deal to Develop Drugs for Obesity and Diabetes

Months after partnering with Sanofi on infectious diseases, Germany-based Evotec has formed another significant partnership with Novo Nordisk. The two companies will combine their forces to develop treatments for diabetes, nonalcoholic steatohepatitis (NASH) and other diseases.

August 22, 2018
·
2 min read
·
Alex Keown
Pharm Country

After Trial Failure, Tonix Sees Glimmer of Hope for Future of PTSD Drug

Shares of Tonix Pharmaceuticals shot up 25 percent in premarket trading this morning after the company announced there may be a future for its late-stage posttraumatic stress disorder treatment Tonmya after a Phase III trial was halted early in July following a data review showed an inadequate response.

August 22, 2018
·
2 min read
·
Alex Keown
Business

Exact Sciences Shares Rocket as Pfizer Agrees to Co-Market Cologuard Colon Cancer Test

Madison, Wisconsin-based EXACT Sciences stocks climbed as much as 21 percent in premarket trading in response to a deal with Pfizer to co-market Exact’s Cologuard non-invasive colon cancer test.

August 22, 2018
·
3 min read
·
Mark Terry
Business

TSOI Taps NFL Veteran to Help Lead CTE Preventative Therapy

Football has received a lot of attention due to the significant number of players who have suffered repeated concussions. California-based Therapeutics Solutions International, Inc. (TSOI) has turned to a veteran player to help lead the development of a concussion preventative.

August 22, 2018
·
3 min read
·
Alex Keown